THIS TRIAL IS NOW CLOSED
Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma
Investigator: Bill G Schmidt, MD
Sponsor: Acceleron Pharma, Inc.
Contact: Anne Bergin, 541-706-6597 or firstname.lastname@example.org
Location: Bend, Oregon (Central Oregon)
The purpose of Part 1 of this study is to evaluate the safety and tolerability of dalantercept in combination with axitinib in patients with advanced renal cell carcinoma (RCC) to determine the recommended dose level of dalantercept in combination with axitinib for Part 2.
The purpose of Part 2 of this study is to determine whether treatment with dalantercept in combination with axitinib prolongs progression free survival (PFS) compared to axitinib alone in patients with advanced renal cell carcinoma (RCC).
- Histologically confirmed, advanced, predominantly clear cell renal cell carcinoma (RCC).
- Part 1: Progression of disease following up to three lines of prior therapy, including at least one approved VEGF receptor tyrosine kinase inhibitor for RCC. Adjuvant therapy is permitted as one line of prior therapy.
- Part 2: Documented Progression on one or two prior therapies defined as:(i) one prior treatment: Either sunitinib or pazopanib inclusive of adjuvant therapy with either agent, if there was documented disease progression during treatment), or (ii) two prior treatments; either sunitinib or pazopanib as listed above and one line of an approved or investigational anticancer immune therapy (e.g., interleukin-2, checkpoint inhibitors or vaccine).
- A minimum of 2 weeks since the last dose of prior therapy (a minimum of 4 weeks since anticancer immune therapy or bevacizumab +/- interferon).
- Measurable disease that is evaluable by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy of at least 12 weeks.
- Clinical laboratory values within acceptable ranges within 72 hours prior to study day 1.
- Clinically significant organ/system disease unrelated to RCC that in the judgment of the investigator should preclude treatment with dalantercept or axitinib.
- Clinically significant cardiovascular risk.
- Known central nervous system (CNS) metastases or leptomeningeal disease. Patients with CNS metastases treated with whole brain radiotherapy, gamma knife, and/or surgery who are considered stable by CNS imaging and are not being treated with corticosteroids within 6 weeks prior to study day 1 may be enrolled to part 1 only.
- Any active malignancy, other than RCC, for which chemotherapy or other anti-cancer therapy is indicated. Patients with adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease-free for at least 5 years will be permitted.
- Any lesion invading or having encasement ≥ 180 degrees around the wall of a major blood vessel as assessed by computed tomography (CT) scan and/or magnetic resonance imaging (MRI).
- Radiotherapy within 2 weeks prior to study day 1.
- Lack of recovery from toxic effects of previous treatment for RCC ≤ grade 1 with the exception of alopecia, unless stabilized under adequate medical control.
- Patients undergoing renal dialysis.
- Major surgery within 4 weeks prior to study day 1 (patients must have recovered completely from any previous surgery prior to study day 1).
- Any active infection requiring parenteral antibiotic therapy within 1 month prior to study day 1 or systemic antibiotics within 2 weeks of study day 1.
- Anti-coagulation therapy (e.g., clopidogrel, dabigatran, warfarin, and heparin).
- Current use of or anticipated inability to avoid potent CTP3A4/5 inhibitors (e.g., grapefruit juice, verapamil, ketoconazole, micronazole, itraconazole, erythromycin, telithromycin, clarithromycin, indinavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, delavirdine) or CTP3A4/5 inducers (carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, phenytoin, amobarbital, nevirapine, primidone, rifabutin, rifampin, St. John’s wort) during participation in the study.
- Peripheral edema within 2 weeks prior to study day 1.
- Bleeding diathesis including clinically significant platelet disorders or active hemoptysis (defined as bright red blood of ≥ 1/2 teaspoon [2.5 mL] in any 24 hour period) within 6 months prior to study day 1. For clinically significant epistaxis within 4 weeks prior to study day 1, no risk of further bleeding must be clearly documented.
- History of hereditary hemorrhagic telangiectasia (HHT).
- Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infections or positive human immunodeficiency virus (HIV) antibody results. Patients with sustained virologic response to HCV treatment or immunity to HBV from prior infection without cirrhosis may be included.
- History of severe (defined as ≥ grade 3, using the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 4.0 [NCI-CTCAE] v4 current active minor version) allergic or anaphylactic reaction or hypersensitivity to recombinant proteins or excipients (10 mM Tris buffered saline) in the investigational agent.
- Any prior treatment with dalantercept or any other agent targeting ALK1 pathway.
- Any prior treatment with axitinib.
- A morbidity (per the prescribing information) that would require starting a patient at a reduced dose of axitinib.
- Treatment with another investigational drug (with the exception of anticancer immune therapy) or device, or approved therapy for investigational use, within 5 times the half-life of the drug or within 3 weeks prior to study day 1 if the half life is not known.
- Pregnant or lactating female patients.
For general inquiries, please contact the BMC Research Department at email@example.com or 877-692-8338.